Cambridge Investment Research Advisors Inc. Purchases 7,796 Shares of SPDR S&P Biotech (XBI)

Cambridge Investment Research Advisors Inc. raised its position in shares of SPDR S&P Biotech (NYSEARCA:XBI) by 29.8% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 33,982 shares of the exchange traded fund’s stock after purchasing an additional 7,796 shares during the quarter. Cambridge Investment Research Advisors Inc. owned 0.07% of SPDR S&P Biotech worth $2,942,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the business. Wechter Feldman Wealth Management Inc. grew its stake in shares of SPDR S&P Biotech by 0.4% during the 2nd quarter. Wechter Feldman Wealth Management Inc. now owns 3,172 shares of the exchange traded fund’s stock valued at $245,000 after purchasing an additional 12 shares during the period. Newman Dignan & Sheerar Inc. grew its stake in shares of SPDR S&P Biotech by 0.6% during the 2nd quarter. Newman Dignan & Sheerar Inc. now owns 8,260 shares of the exchange traded fund’s stock valued at $638,000 after purchasing an additional 50 shares during the period. Willingdon Wealth Management lifted its position in shares of SPDR S&P Biotech by 1.8% during the 2nd quarter. Willingdon Wealth Management now owns 6,541 shares of the exchange traded fund’s stock valued at $505,000 after buying an additional 118 shares in the last quarter. Bank of New York Mellon Corp lifted its position in shares of SPDR S&P Biotech by 1.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 19,274 shares of the exchange traded fund’s stock valued at $1,488,000 after buying an additional 197 shares in the last quarter. Finally, Vestor Capital LLC lifted its position in shares of SPDR S&P Biotech by 0.5% during the 2nd quarter. Vestor Capital LLC now owns 38,663 shares of the exchange traded fund’s stock valued at $2,984,000 after buying an additional 208 shares in the last quarter.

SPDR S&P Biotech (NYSEARCA:XBI) traded down $0.03 during mid-day trading on Friday, hitting $81.43. The stock had a trading volume of 1,140,000 shares. SPDR S&P Biotech has a 12-month low of $58.66 and a 12-month high of $88.98.

COPYRIGHT VIOLATION NOTICE: “Cambridge Investment Research Advisors Inc. Purchases 7,796 Shares of SPDR S&P Biotech (XBI)” was originally published by Transcript Daily and is the property of of Transcript Daily. If you are viewing this news story on another site, it was illegally copied and republished in violation of US & international copyright and trademark laws. The original version of this news story can be viewed at https://transcriptdaily.com/2017/11/18/cambridge-investment-research-advisors-inc-purchases-7796-shares-of-spdr-sp-biotech-xbi.html.

About SPDR S&P Biotech

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

Institutional Ownership by Quarter for SPDR S&P Biotech (NYSEARCA:XBI)

Receive News & Ratings for SPDR S&P Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply